Consulte a su mdico en caso de dudas y solicite orientacin a su qumico farmacutico
Other research highlights: 30% of GLP-1 users tested positive for SIBO or IMO even after accounting for diabetes (5) GLP-1 medicines caused microbiome changes and altered metabolism in mice (6) GLP-1 medicines tested in humans only had noticeable microbiome changes by 48 weeks (7) Despite not necessarily having slower gut motility, one study found that 88.9% of obese patients had SIBO (8) A meta analysis of people with IBS symptoms, found that up to 78% of people had SIBO, many of whom were undiagnosed (9) Overall, Sun and colleagues (1) could not prove a mechanistic link between GLP-1 medications and SIBO, however they did find that SIBO was twice as likely in GLP-1 users
For laboratory buyers and independent investigators, sourcing a reliable mod grf 1 29 peptide blend requires careful attention to purity, stability, and testing standards
Current evidence suggests that dulaglutide and extended-release formulations generally demonstrate lower nausea rates compared to twice-daily exenatide or higher-dose semaglutide and liraglutide
Embrace the journey, stay consistent, and celebrate every milestone along the way
